Chemoradiotherapy has been a standard modality for inoperable locally advance esophageal carcinoma. The goal of this randomized control study is to compare the feasibility, and survival benefits of whole-course immunonutrition combined with chemoradiotherapy±ICIs for local advanced patients with inoperable esophageal squamous cell carcinoma. The main questions it aims to answer are: • If the feasibility and safety of whole-course immunonutrition combined with chemoradiotherapy±ICIs is better. • If the survival benefits (1, 2 and 3-years progression free survival) of whole-course immunonutrition combined with chemoradiotherapy±ICIs is longer. The Experimental group will receive a combination immunonutrition of omega-3 fatty acids, and glutamine, whereas the control group will receive standard formula.
18-85 years old;
Eastern Cooperative Oncology Group (ECOG) 0-2;
Esophageal squamous cell carcinoma;
cT2-4aN0-3M0 (AJCC 8th) confirmed by radiological examination;
younger than 18 years old or older than 85 years old;
ECOG>2;
Esophageal adenocarcinoma, small-cell cancer and other pathological types;
cT1anyNM0, cT4banyNM0, c anyTanyNM0 confirmed by radiological examination;
* 18-85 years old; * Eastern Cooperative Oncology Group (ECOG) 0-2; * Esophageal squamous cell carcinoma; * cT2-4aN0-3M0 (AJCC 8th) confirmed by radiological examination; * initial unresectable at initial diagnosis confirmed by thoracic surgeons; * Treatment naive; * No contraindications for adjuvant chemoradiotherapy; * Signature of inform consent.
Case-control
Prospective
Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs
Dietary supplementThe Experimental group received a combination of omega-3 fatty acids, and glutamine, whereas the control group received standard formula.
Rate of adverse events
Rate of adverse events (CTCAE V4.0)
Disease Control Rate
Disease Control Rate
1-, 2-, 3-year Progression-free survival rate (PFS).
1-, 2-, 3-year Progression-free survival rate (PFS).
Click on the lead sponsor to view all of their trials.
